VEGFA and neoplasm: By targeting vascular endothelial growth factor (VEGF), Bevacizumab reduces tumor blood supply, making it a cornerstone in the current mCRC treatment paradigm (Chionh et al., 2022; de Rauglaudre et al., 2022).